My Cancer Genome: Genetically Informed Cancer Medicine

  • Home
  • DIRECT
  • About Us
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Anaplastic Large Cell Lymphoma
  • Basal Cell Carcinoma
  • Bladder Cancer
  • Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Colorectal Cancer
  • GIST
  • Gastric Cancer
  • Glioma
  • Inflammatory Myofibroblastic Tumor
  • Lung Cancer
  • Medulloblastoma
  • Melanoma
  • Myelodysplastic Syndromes
  • Neuroblastoma
  • Ovarian Cancer
  • Prostate Cancer
  • Rhabdomyosarcoma
  • Thymic Carcinoma
  • Thyroid Cancer
  • Molecular Medicine
    • Anticancer Agents
    • Circulating Tumor DNA
    • Detecting Gene Alterations in Cancers
    • Immunotherapy in Cancer
    • Overview of Targeted Therapies for Cancer
    • Pathways
    • Types of Molecular Tumor Testing
  • Take Our Survey
  • Glossary
  • News
  • Our Team
  • Acknowledgements

DNA Damage/Repair

DNA damage may result from both endogenous factors (e.g., replication errors, oxidative deamination, and reactive oxygen species) and exogenous factors (e.g., UV light and radiation). The processes of DNA repair involve the identification of DNA damage and subsequent restoration by several processes including nucleotide excision repair, base excision repair, non-homologous-end-joining, and homologous recombination depending on the type of DNA damage (single stranded DNA break vs. double stranded DNA break. If damage to DNA cannot be repaired, the cell will undergo cell cycle arrest, senescence, or programmed cell death.

DDR

Figure 1. The cell signaling pathways that are involved in DNA damage are displayed. Excision repair cross-complementation group genes (ERCC-1/-4), X-ray repair complementing defective repair in Chinese hamster cells genes (XRCC-1/-5/-6), poly(ADP-ribose) polymerase 1 (PARP1), the Fanconi anemia gene complex (FANC-A/-C/-D2/-E/-F/-G/-L), Rad51 recombinase (RAD51), ATM serine/threonine kinase (ATM), ATR serine/threonine kinase (ATR), protein kinase, DNA-activated catalytic polypeptide (PRKDC), and the breast cancer, early onset genes (BRCA1/2) are included in the DNA damage pathway. Specific nodes in the pathway that are therapeutically actionable are noted. Click here to open a larger version of this image in a new window.

Upstream Pathways

  • Cell cycle control
  • JAK/STAT signaling
  • Kinase fusions
  • MAP kinase signaling
  • PI3K/AKT1/MTOR signaling
  • Receptor tyrosine kinase/growth factor signaling

Diseases in Which Pathway is Aberrantly Activated

  • Myelodysplastic syndromes

Therapies That Target This Pathway

  • PARP inhibitors

Genes Involved in the Pathway

  • ATM
  • ATR
  • ATRX
  • BRCA1
  • BRCA2
  • BRIP1
  • EMSY
  • FANCA
  • FANCC
  • FANCD2
  • FANCE
  • FANCF
  • FANCG
  • FANCL
  • MDM2
  • MDM4
  • MLH1
  • MUTYH
  • NPM1
  • PALB2
  • PP2R1A
  • RAD50
  • RAD51
  • STAG2

Last Updated: May 24, 2016

Disclaimer: The information presented at MyCancerGenome.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.

  • MCG Home |
  • About Us |
  • Acknowledgments |
  • Give |
  • Site Map |
  • Legal |
  • APIs and Licensing
My Cancer Genome is managed by the Vanderbilt-Ingram Cancer Center   Copyright © 2010 - 2017 MY CANCER GENOME